The genital herpes market is expected to grow significantly owing to the increase in diagnosed genital herpes cases per year, awareness, and anticipated launch of emerging therapies by key players such as AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, GlaxoSmithKline, and others.
LAS VEGAS, Nov. 21, 2022 /PRNewswire/ -- DelveInsight's Genital Herpes Market Insights report includes a comprehensive understanding of current treatment practices, genital herpes emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 8MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan, and China].
Key Takeaways from the Genital Herpes Market Report
- As per DelveInsight analysis, the genital herpes market size in the 7MM + China was approximately USD 1,125 million in 2021.
- According to the assessment done by DelveInsight, the estimated total genital herpes diagnosed cases in the 7MM + China was approximately 1.6 million in 2021.
- Leading genital herpes companies such as AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, GlaxoSmithKline, and others are developing novel genital herpes drugs that can be available in the genital herpes market in the coming years.
- The promising genital herpes therapies in the pipeline include AIC-316 (pritelivir), UB-621, HDIT101, SIMPLIRIX (GSK208141), GEN-003, HerpV (AG-707), VCL-HB01, SP-0148, and others.
- In August 2022, Rational Vaccines Inc. announced the start of an observational clinical trial to determine the baseline characteristics of patients with recurrent symptomatic herpes simplex virus type 2 infection (HSV-2).
Discover which therapies are expected to grab the major genital herpes market share @Genital Herpes Market Report
Genital Herpes Overview
Genital herpes is a chronic sexually transmitted infection (STI) characterized by genital blisters and open sores (lesions). Among the genital herpes causes, two types of herpes simplex virus (HSV), HSV-1 and HSV-2, play an important role. The virus becomes active for a short period before going dormant; when active, it travels to the surface of the infected area (skin or mucous membrane) and replicates itself. This is referred to as "shedding" because the viruses can rub off and spread to another person at this stage.
In most cases, genital herpes is asymptomatic, but it can also present with mild genital herpes symptoms, leading to the infection going unnoticed. Most genital herpes transmission occurs from asymptomatic patients or patients whose genital herpes symptoms have not been recognized.
Due to the inaccuracy of diagnostic tests, genital herpes diagnosis is difficult, especially in patients with no genital herpes symptoms.
Genital Herpes Epidemiology Segmentation
DelveInsight estimates that there were approximately 1.6 milliondiagnosed cases of genital herpes in the 7MM + China in 2021.
Among the 8MM, the highest number of prevalent HSV-infected cases was observed in China in 2021.
The genital herpes market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM + China segmented into:
- Prevalent HSV infected cases
- Symptomatic Genital Herpes cases per year
- Genital Herpes cases, by gender
- Diagnosed Genital Herpes cases per year
- Total recurrent cases of Genital Herpes
- Treated patient pool of Genital Herpes
Download the report to understand which factors are driving genital herpes epidemiology trends @Genital Herpes Epidemiological Insights
Genital Herpes Treatment Market
Genital herpes treatment is assigned to patients based on the type of HSV that caused the infection and the number of episodes of infection. Different regimens are recommended for the first clinical episode, episodic therapy and suppressive therapy; different therapeutic regimens are recommended for HSV-1 and HSV-2. There are also specific guidelines for managing complications associated with genital herpes, such as HIV infection, antiviral-resistant HSV infection, herpes during pregnancy, and neonatal pregnancy.
Although genital herpes has no known cure, but daily use of antiviral medications can prevent or shorten outbreaks. Antiviral medications can also reduce the likelihood of it spreading to others. For genital herpes treatment, effective oral antiviral medications are available. These genital herpes medications provide clinical benefits but do not cure the disease. These medications can be used for either short-term or long-term suppressive therapy.
The oldest and most researched genital herpes medication is acyclovir (ZOVIRAX), a guanosine analog that inhibits viral DNA synthesis. It has a low bioavailability and a short half-life, requiring frequent dosing. Valacyclovir (VALTREX), a prodrug metabolizing to acyclovir, has higher bioavailability than acyclovir and requires less frequent dosing. Moreover, FAMVIR (famciclovir) is a purine analog with high bioavailability. They all have rare, similar side effects, such as nausea, vomiting, headache, and diarrhea.
To know more about genital herpes medication, visit @Antiviral Drugs for Genital Herpes Treatment
Genital Herpes Pipeline Therapies and Key Companies
- AIC-316 (pritelivir): AiCuris
- UB-621: United BioPharma
- HDIT101: Heidelberg ImmunoTherapeutics
- SIMPLIRIX (GSK208141): GlaxoSmithKline
- GEN-003: Genocea Biosciences
- HerpV (AG-707): Agenus
- VCL-HB01: Fresh Tracks Therapeutics
- SP-0148: Sanofi
Learn more about the FDA-approved drugs for genital herpes treatment @Genital Herpes Treatment Drugs
Genital Herpes Market Dynamics
Genital herpes is a common sexually transmitted disease. As the population of various geographies grows, so does the prevalence of health issues worldwide. As a result of the increasing prevalence of diseases, the genital herpes market will increase in the coming years.
In addition to a rapidly growing population, the increased awareness and diagnosis would present appealing potential opportunities for the genital herpes market.
However, there are significant unmet needs in the genital herpes market. Although genital herpes is an STI, it has a significant impact on patients' mental and social health and sexual health. Furthermore, the diagnostic tests for genital herpes are inaccurate. Most HSV-infected people are asymptomatic or have very mild symptoms that go unnoticed or are misdiagnosed as another skin condition.
Another significant gap in the genital herpes market is the lack of preventive and curative therapies. Moreover, the emerging pipeline for genetic herpes is also not very strong, with only a few therapies in development, most of which are being developed for symptom management and symptom reduction. As a result, in the current genital herpes market, there is no preventive or curative genital herpes treatment among emerging drugs.
Furthermore, several generics and off-label drugs are available on the genital herpes market. The availability of generics for these and previously marketed products, as well as off-label therapies, may stymie sales of new therapies in the genital herpes market. Hence, these factors may affect the growth of the genital herpes market.
Report Metrics | Details |
Study Period | 2019-2032 |
Coverage | 8MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China] |
Base Year | 2021 |
Genital Herpes Market CAGR | 3.2 % |
Genital Herpes Market Size in 2021 | USD 1,125 Million |
Key Genital Herpes Companies | AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, GlaxoSmithKline, and others |
Key Genital HerpesTherapies | AIC-316 (pritelivir), UB-621, HDIT101, SIMPLIRIX (GSK208141), GEN-003, HerpV (AG-707), VCL-HB01, SP-0148, and others |
Scope of the Genital Herpes Market Report
- Therapeutic Assessment: Genital Herpes current marketed and emerging therapies
- Genital Herpes Market Dynamics: Genital Herpes market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Genital Herpes Market Access and Reimbursement
Discover more about drugs for genital herpes treatment in development @Clinical Trials for Genital Herpes Treatment
Table of Contents
1. | Genital Herpes Market Key Insights |
2. | Genital Herpes Market Report Introduction |
3. | Genital Herpes Market Overview at a Glance |
4. | Genital Herpes Market Executive Summary |
5. | Disease Background and Overview |
6. | Genital Herpes Treatment and Management |
7. | Genital Herpes Epidemiology and Patient Population |
8. | Patient Journey |
9. | Genital Herpes Emerging Drugs |
10. | 8MM Genital Herpes Market Analysis |
11. | Genital Herpes Market Outlook |
12. | Potential of Current and Emerging Therapies |
13. | KOL Views |
14. | Genital Herpes Market Drivers |
15. | Genital Herpes Market Barriers |
16. | Unmet Needs |
17. | SWOT Analysis |
18. | Appendix |
19. | DelveInsight Capabilities |
20. | Disclaimer |
21. | About DelveInsight |
Related Reports
Genital Herpes Epidemiology Forecast
Genital Herpes Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the genital herpes epidemiology trends.
Genital Herpes Pipeline
Genital Herpes Pipeline Insight - 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key genital herpes companies, including Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, GlaxoSmithKline, among others.
Chlamydia Pipeline
Chlamydia Pipeline Insight - 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chlamydia companies, including Evofem Biosciences, QureTechBio, Vault Pharma, among others.
Chlamydia Infections Pipeline
Chlamydia Infections Pipeline Insight - 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chlamydia infections companies, including Melinta Therapeutics, Abera Bioscience, Prokarium, Blue willow Biologics, Microbiotix, Abivax, among others.
Human Papillomavirus Infection Market
Human Papillomavirus Infection Market Insights, Epidemiology, and Market Forecast - 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key human papillomavirus infection companies, including Vaccibody As, Genexine, Transgene, Inovio Pharmaceuticals, among others.
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Market
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Market Insights, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key human immunodeficiency virus type 1 (HIV-1) infection companies, including United BioPharma, Gilead sciences, Taimed Biologics, Merck, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/genital-herpes-market-to-exhibit-growth-at-a-cagr-of-3-2-by-2032--delveinsight-301683624.html
